Citrate treatment reduces endothelial death and inflammation under hyperglycaemic conditions.

Bryland, Anna; Wieslander, Anders; Carlsson, Ola; Hellmark, Thomas; Godaly, Gabriela

Published in: Diabetes & Vascular Disease Research

DOI: 10.1177/1479164111424297

2012

Link to publication

Citation for published version (APA):
Bryland, A., Wieslander, A., Carlsson, O., Hellmark, T., & Godaly, G. (2012). Citrate treatment reduces endothelial death and inflammation under hyperglycaemic conditions. Diabetes & Vascular Disease Research, 9(1), 42-51. https://doi.org/10.1177/1479164111424297

Total number of authors: 5
Citrate treatment reduces endothelial death and inflammation under hyperglycaemic conditions
Anna Bryland, Anders Wieslander, Ola Carlsson, Thomas Hellmark and Gabriela Godaly

Diabetes and Vascular Disease Research 2012 9: 42 originally published online 1 November 2011
DOI: 10.1177/1479164111424297

The online version of this article can be found at:
http://dvr.sagepub.com/content/9/1/42

Published by:

SAGE

http://www.sagepublications.com

Additional services and information for Diabetes and Vascular Disease Research can be found at:
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Email Alerts: http://dvr.sagepub.com/cgi/alerts
Subscriptions: http://dvr.sagepub.com/subscriptions
Reprints: http://www.sagepub.com/journalsReprints.nav
Permissions: http://www.sagepub.com/journalsPermissions.nav
Citations: http://dvr.sagepub.com/content/9/1/42.refs.html

>> Version of Record - Dec 12, 2011
OnlineFirst Version of Record - Nov 2, 2011
OnlineFirst Version of Record - Nov 1, 2011
What is This?
Introduction

Diabetic patients have a high risk of hyperglycaemia, a condition that is considered to be a major cause of cardiovascular disease (CVD). Diabetes is characterised by the development of specific micro- and macrovascular complications and by high incidence of accelerated atherosclerosis. Hyperglycaemia-caused endothelial dysfunction plays a key role in the pathogenesis of diabetes complications and numerous studies have linked the activation of protein kinase C (PKC) to the diabetic state. PKC activation regulates vascular permeability and is involved in endothelial cell activation, abnormal angiogenesis, synthesis of the extracellular matrix, excessive apoptosis, leukocyte adhesion and cytokine production.

In addition to glucose itself, increased vascular atherosclerosis is further caused by the degradation products (GDPs) of glucose. Reactive GDPs, such as 3,4-dideoxyglucosone-3-ene (3,4-DGE), react with proteins to form advanced glycation end products (AGEs) in the circulation.

Severely hyperglycaemic patients typically suffer from complications such as infections and decreased wound healing. Postoperative hyperglycaemia is also a recognised risk factor for postoperative surgical site infections that leads to increased rehospitalisation, prolonged length of hospital stay and increased health-care costs. Highly reactive GDPs, such as 3,4-DGE, react instantly with different molecules, while others, such as 3-deoxyglucosone (3-DG), remain in the circulation. The amount of 3-DG in the serum of a healthy human is low, but increases two-fold with disease such as diabetes and threefold in uraemia. Furthermore, 3-DG is converted to the more reactive 3,4-DGE through equilibrium. 3,4-DGE was recently demonstrated to decrease neutrophil viability, impair immune responses and decrease bacterial killing. Hyperglycaemia
and GDPs are further known to induce caspase-mediated apoptosis and oxidative stress in endothelial cells and neutrophils.\(^8,^{14,15}\) AGE activation of endothelial cells stimulates a host of proinflammatory events, such as the secretion of tumour necrosis factor alpha (TNF\(\alpha\)) and interleukin-6 (IL-6), but also the induction of chemotactic cytokines such as interleukin-8 [IL-8; chemokine (C-X-C motif) ligand 8 (CXCL8)] and chemokine (C-C motif) ligand 2 (CCL2; MCP-1), leading to increased endothelial inflammation and leukocyte recruitment.\(^{16,17}\) Hyperglycaemia-induced reactive oxygen species (ROS) production leads also to upregulation of the intercellular adhesion molecule-1 (ICAM-1) and vascular cellular adhesion molecule-1 (VCAM-1).\(^{18}\)

The sum of these events leads to adhesion and migration of leukocytes across endothelial cells, which play an important role in the development of atherosclerosis.\(^{19}\)

Citrate is an intermediate in the citric acid cycle and is widely used in the food and drug industry because of its buffer, anticoagulant and antioxidant capacities. As a chelator, citrate is able to bind calcium and metals that catalyse the production of ROS. Different chelators have been evaluated against the development of diabetic complications in numerous in vivo studies, but the results are not uniformly positive.\(^{20-22}\) Citrate addition during dialysis was shown to improve clinical parameters and to decrease inflammation,\(^{23-25}\) but there are no studies published on citrate treatment during hyperglycaemic conditions. Another antioxidant with chelating properties is gluconate, which was recently shown to improve endothelial function.\(^{26}\) Although the clinical usage of citrate is gaining popularity, in-depth knowledge about its anti-inflammatory mechanisms are unknown. The aim of this study was to investigate the anti-inflammatory capacity of citrate and the combination of citrate and gluconate on hyperglycaemia- or 3,4-DGE-damaged endothelial cells.

**Methods**

**Cell culture**

Primary human umbilical vein endothelial cells (HUVECs) (Clonetics; Lonza Cologne GmbH, Cologne, Germany) were obtained and cultured in endothelial cell growth medium (EGM\(^8\)-2; Clonetics; Lonza Cologne GmbH, Cologne, Germany) supplemented with the EGM\(^8\)-2 BulletKit\(^\text{®}\) (hydrocortisone, 0.4% human fibroblast growth factor-basic (hFGF-b); 0.1% vascular endothelial growth factor (VEGF); 0.1% recombinant analogue of insulin-like growth factor-1 (I\(\text{GF}-1\)); 0.1% ascorbic acid; 0.1% heparin; 2% fetal bovine serum (FBS); 0.1% hEGF and 0.1% gentamicin sulfate and amphotericin-B (GA-1000); incubation: 37°C, 5% CO\(_2\) (Clonetics, Lonza Cologne GmbH, Cologne, Germany). The cells were used at passages 2–5, according to the manufacturer’s instructions.

**Dose-response evaluation**

Endothelial cells were exposed to different concentrations of citrate (0.25, 0.8, 1.0, 1.5, 2.0 and 5.0 mM) and glucose (0.25, 0.8, 1.0, 1.5, 2.0 and 5.0 mM) for 48 h. The portions of living cells were evaluated by the neutral red (NR) uptake assay.\(^{27}\)

**Sample preparation**

Endothelial cells were cultured in six-well plates (BD Biosciences, Stockholm, Sweden) until approximately 80% confluent. The cells were treated with 30 mM D-glucose (Merck KGaA, Darmstadt, Germany) or a combination (henceforth referred to as the ‘CAG combination’) of 0.8 mM citrate (trisodium citrate dihydrate; Merck KGaA, Darmstadt, Germany) and 1 mM gluconate (sodium gluconate; Jungbunzlauer AG, Basel, Switzerland) dissolved in supplemented EGM-2 medium followed by incubation (37°C, 5% CO\(_2\)) for 48 h. GDP concentration was chosen according to previous studies\(^8\) and the concentrations of citrate and the CAG combination were selected after dose-response studies (supplementary Figure 1). Endothelial cells treated with EGM-2 medium were used as a negative control. As an additional control, the cells were also treated with 0.8 mM citrate or with the CAG combination.

**Detection of apoptosis and necrosis**

After incubation with different combinations, the cells were detached [trypsin-ethylenediamine tetraacetic acid (EDTA) for about 5 min at room temperature, followed by the addition of a trypsin inhibitor], washed in phosphate-buffered saline (PBS; twice, 5 min, 1000 rpm) and stained with annexin V-Alexa Fluor®488 (Life Technologies Europe BV, Stockholm, Sweden) (1:100, 15 min in the dark on ice) to test detect apoptosis and 7-aminoactinomycin D (7-AAD; BD Via-Probe, BD Pharmingen Biosciences, San Diego, California, USA) until approximately 80% confluent. The cells were treated with 30 mM D-glucose (Merck KGaA, Darmstadt, Germany) or a combination (henceforth referred to as the ‘CAG combination’) of 0.8 mM citrate (trisodium citrate dihydrate; Merck KGaA, Darmstadt, Germany) and 1 mM gluconate (sodium gluconate; Jungbunzlauer AG, Basel, Switzerland) dissolved in supplemented EGM-2 medium followed by incubation (37°C, 5% CO\(_2\)) for 48 h. GDP concentration was chosen according to previous studies\(^8\) and the concentrations of citrate and the CAG combination were selected after dose-response studies (supplementary Figure 1). Endothelial cells treated with EGM-2 medium were used as a negative control. As an additional control, the cells were also treated with 0.8 mM citrate or with the CAG combination.
Cells were treated with glucose/3,4-DGE and citrate/CAG as previously described and washed with PBS containing 0.2 mM phenylmethylsulfonyl fluoride (PMSF), 1 µg/ml peptatin A, 5 µg/ml leupeptin (Sigma-Aldrich Sweden AB, Stockholm, Sweden) and a complete protease inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, Germany) and lysed in modified radio immunoprecipitation assay (RIPA) [50 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), 150 mM NaCl, 2 mM EDTA, 50 mM ZnCl₂, 1% nonyl phenoxypolyethoxylethanol (NP-40), 0.1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS) containing the same protease inhibitors]. Protein concentrations were measured with the detergent compatible (DCTM) protein assay (Bio-Rad Laboratories, Hercules, California, USA). Equal amounts of protein were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and blotted onto polyvinylidene fluoride (PVDF) membranes. Membranes were saturated with non-fat dry milk or bovine serum albumin (BSA) and incubated with mouse monoclonal antibodies against PKC-βIII (Millipore AB, Solna, Sweden) (all 1:500–1000) or mouse anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody as loading control (1:3000–5000; Novus Europe, Cambridge, UK). Bound antibodies were detected with rabbit anti-mouse horseradish peroxidase (HRP)-conjugated antibody (1:50,000–200,000; Novus Europe, Cambridge, UK) using the ECL Plus Western blotting reagent (GE Healthcare UK Ltd, Little Chalfont, UK) and the GelDoc equipment (Bio-Rad Laboratories AB, Sundbyberg, Sweden). To quantify protein levels, band intensity was measured with the ImageJ software version 1.24 (National Institutes of Health, Bethesda, Maryland, USA) and normalised against GAPDH. If required, membranes were stripped with Restore Western Blot Stripping Buffer (Thermo Fisher Scientific Inc., Rockford, Illinois, USA), blocked and reprobed with new antibodies.

**ICAM-1 expression**

After exposure to different combinations, the endothelial cells were enzymatically detached according to the manufacturer’s instructions and washed in PBS (twice, 5 min, 1000 rpm) followed by the addition of antibodies for expression of the VCAM-1 (10 µg/ml) or ICAM-1 (10 µg/ml) adhesion molecules (R&D Systems, Copenhagen, Denmark). Cells were incubated in the dark on ice for 30 min, then washed in PBS (twice, 5 min, 1000 rpm), and stained with secondary antibody rabbit anti-mouse IgG-fluorescein isothiocyanate (FITC) rabbit f(ab′)₂ antibody (10 µg/ml) (Dako Sweden AB, Stockholm, Sweden) and incubated for 15 min in the dark on ice. After an additional washing step (PBS, twice, 5 min, 1000 rpm) the expression of ICAM-1 and VCAM-1 was analysed using the EPICS® XL-MCL™ flow cytometer (Beckman Coulter Inc., Brea, California, USA), and fluorescence intensity was standardised using Flow-Set fluorospheres (Beckman Coulter Inc., Brea, California, USA). An IgG negative control (Life Technologies Europe BV, Stockholm, Sweden) was used as a negative control.

**Neutrophil migration**

HUVECs were grown on Transwell® inserts (12-well, 3 µM pore size; Sigma-Aldrich Chemie GmbH, Munich,
Germany) in EGM-2 medium, as previously described. As a control, cell viability was analysed by trypan blue exclusion assay according to the manufacturer’s instructions (Sigma-Aldrich Chemie GmbH, Munich, Germany). The cell growth medium was replaced with medium containing glucose, 3,4-DGE or combinations of glucose/3,4-DGE and citrate/CAG as in the experiments above, and the cells were incubated for 48 h. Cells treated with medium and cells treated with 0.8 mM citrate or the CAG combination were used as negative controls. Human neutrophil isolation and transmigration assays were performed as previously described. Briefly, 0.5 ml fresh culture medium was added to the top well, and fresh medium or medium containing the different combinations and Escherichia coli (10^8 bacteria/cell, 1.5 ml) was added to the bottom well. The cluster plates were then incubated at 37 °C and at 5% CO₂ atmosphere for 24 h, a time that induced maximal neutrophil migration across the endothelial monolayer. Neutrophils (1.5 × 10^6, 0.5 ml) were added to the top well. After 3 h, samples were taken from the bottom well for neutrophil counting by Cell Counter (Sysmex UK Ltd, Milton Keynes, UK) and analysed for cytokines.

Cytokine secretion

Secretion of IL-6 and CXCL8 by the infected endothelial cells was quantified in supernatants by enzyme-linked immunosorbent assay (ELISA; R&D Systems, Sweden) according to the manufacturer’s instructions.

Statistical analysis

All data are shown as mean ± SEM. Each experiment was repeated 3–4 times. The statistical difference was investigated using the Mann–Whitney U test (***p ≤ 0.001, **p < 0.01, *p < 0.05, ns = not significant).

Results

Evaluation of optimal concentrations

To determine optimal antioxidant concentrations, we analysed the effect of the antioxidants on cell survival by dose-response curve studies (supplementary Figure 1). Endothelial cell viability was not affected by citrate or gluconate concentrations up to 5 mM (supplementary Figure 1). Citrate treatment decreases cell mortality

To investigate whether citrate or the combination of citrate and gluconate influence the cause of cell death, endothelial cells were exposed to glucose and 3,4-DGE in the presence or absence of citrate or CAG combination (Figure 1). Natural cell death (medium control) was 22%, of which 5%
was caused by apoptosis and 17% was caused by necrosis. Incubation of the endothelial cells with glucose or 3,4-DGE significantly increased the total number of dead cells to 46% and to 63% respectively compared to control (Figure 1a and 1b).

Glucose treatment of HUVECs increased the fraction of both apoptotic and necrotic cells (up to 11% and to 34%), while 3,4-DGE-treated HUVECs increased higher fractions of both apoptotic and necrotic cells (up to 14% and to 49%) compared to the control (Figure 1a and Figure 2a). The presence of citrate or CAG combination decreased the glucose-induced cell death drastically. Citrate treatment decreased the apoptotic fraction down to the level of the control (6%), as did the CAG combination which decreased glucose-induced cell death to 5%. Glucose-induced necrosis was decreased to 26% and 27% with citrate and CAG combination, respectively. The treatment of 3,4-DGE-damaged endothelial cells with citrate or CAG combination significantly reduced total cell death to 35% (Figure 1b). The effect was most prominent on 3,4-DGE-induced necrosis, which was reduced to 25% with citrate treatment and to 26% with the CAG combination. 3,4-DGE-induced endothelial apoptosis was reduced to 9% with both citrate treatment alone or the CAG combination (Figure 1b and Figure 2b). The addition of citrate or CAG combination to control endothelial cells did not affect cell viability (data not shown).

### Table 1. ICAM-1 expression on endothelial cells

| Additive to the cells | Mean ± SEM | p value  |
|-----------------------|------------|---------|
| None                  | 8.8 ± 0.08 | –       |
| Glucose               | 9.5 ± 0.01 | < 0.01  |
| Glucose and citrate   | 9.0 ± 0.04 | < 0.01  |
| Glucose and citrate/gluconate | 8.7 ± 0.01 | < 0.01 |
| 3,4-DGE               | 9.8 ± 0.04 | < 0.05  |
| 3,4-DGE and citrate   | 9.6 ± 0.01 | ns       |
| 3,4-DGE and citrate/gluconate | 8.5 ± 0.04 | <0.05  |

3,4-DGE: 3,4-dideoxyglucosone-3-ene, ICAM-1: intercellular adhesion molecule-1.

aThe results are the mean (± SEM) of four separate experiments;
bcompared to the negative control; ccompared to glucose-treated cells;
dcompared to 3,4-DGE- and citrate-treated cells (ns = not significant);
ecompared to 3,4-DGE- and citrate/gluconate-treated cells.
Citrate decreases PKC-βII expression

PKC activation is involved in the development of vascular dysfunction and plays a key role in the pathophysiology of diabetic vascular complications. Endothelial treatment with glucose or 3,4-DGE increased PKC-βII expression compared to unstimulated cells (Figure 2b and 2c). The addition of citrate or CAG combination during endothelial treatment with glucose or 3,4-DGE kept PKC-βII expression down to background level.

Citrate decreases endothelial ICAM-1 expression

We investigated if citrate treatment of endothelial cells during conditions of hyperglycaemia affects ICAM-1 and VCAM-1. Exposure of endothelial cells to glucose or 3,4-DGE significantly upregulated ICAM-1 expression (Figure 3 and Table 1), but did not affect VCAM-1 expression (data not shown). Glucose-induced ICAM-1 expression was significantly reduced with the addition of citrate or CAG combination. ICAM-1 expression was also reduced by the presence of CAG combination in 3,4-DGE-damaged cells. However, gluconate alone did not reduce glucose or 3,4-DGE-increased endothelial ICAM-1 expression, and citrate alone did not reduce 3,4-DGE-increased endothelial ICAM-1 expression. Treatment of control endothelial cells with citrate, gluconate or CAG combination did not increase ICAM-1 expression (data not shown).

Citrate decreases neutrophil migration across infected cells

To investigate how glucose and 3,4-DGE affect endothelial cell function, we cultured HUVECs in the Transwell® model and investigated if infection-induced neutrophil diapedesis could be affected by glucose (Figure 4a) or 3,4-DGE (Figure 4b) in the presence or absence of citrate or CAG combination. Infection increased neutrophil diapedesis by 48%, but was not further affected by glucose or 3,4-DGE treatment. However, neutrophil migration was significantly reduced by citrate or CAG treatment of infected and glucose or 3,4-DGE-treated endothelial cells ($p < 0.01$ and $p < 0.001$). Treatment of infected endothelium with citrate or CAG combination reduced neutrophil diapedesis to the same extent, while neither citrate nor CAG combination treatment of non-infected control cells had any effect (data not shown).

Citrate decreases inflammation

Endothelial cells were treated with glucose or 3,4-DGE with or without citrate or CAG combination to further investigate the effect of glucose and 3,4-DGE on endothelial dysfunction during inflammation. Secretion of the pro-inflammatory cytokine, IL-6, and the chemotactic cytokine, CXCL8, was used as a model of inflammation. Basal IL-6 secretion (negative control) was 33 pg/ml (Figure 5a and 5b). An infection significantly increased IL-6 secretion to 146 pg/ml and IL-6 secretion increased even further to 235 pg/ml with glucose (Figure 5a) and to 208 pg/ml with 3,4-DGE (Figure 5b). Using citrate alone on infected...
endothelial cells in the presence of glucose or 3,4-DGE reduced IL-6 secretion to 173 and 135 pg/ml and the CAG combination reduced cytokine secretion even further to 138 and 118 pg/ml, respectively (Figure 5a and 5b). The CAG combination significantly decreased the level of IL-6 secretion from non-infected endothelial cells while citrate treatment alone had a lesser effect, 138 pg/ml and 173 pg/ml, respectively ($p = 0.048$, data not shown).

Endothelial cells secrete the neutrophil chemokine CXCL8 upon infection. The basal level of CXCL8 in control samples was 295 pg/ml, which increased to 1354 pg/ml upon infection. Glucose or 3,4-DGE treatment of infected endothelial cells increased CXCL8 secretion slightly more, but the increase was not significant. Citrate treatment of infected cells exposed to glucose or 3,4-DGE did not decrease CXCL8 secretion significantly. However, the CAG combination significantly decreased CXCL8 secretion from infected cells exposed to glucose or 3,4-DGE to 788 and 576 pg/ml, respectively ($p < 0.05$ and $p < 0.01$ respectively).

**Discussion**

Endothelial dysfunction is an early manifestation of vascular atherosclerosis and cardiovascular disease. Confirming previous studies, we found that hyperglycaemia and 3,4-DGE significantly increased both necrosis and apoptosis, with 3,4-DGE causing the highest cell death. To evaluate the capacity of citrate and gluconate on endothelial survival, hyperglycaemia-damaged endothelial cells were treated with these compounds and analysed for apoptosis and necrosis. Remarkably, we found that endothelial treatment with citrate or with the CAG combination decreased hyperglycaemia and 3,4-DGE induced cell death by up to 50%. The mechanism behind citrate-induced reduction in cell death was shown to involve a reduced PKC-$\beta$II expression. PKC-$\beta$II is a member of the superfamily of serine/threonine kinases that respond to Ca$^{2+}$ and diacylglycerol (DAG) for downstream signalling.$^{10}$ To be activated, PKC must be properly phosphorylated, but while phosphorylations at the activation site are dispensable for activity,
phosphorylation of the turn motif is absolutely required to maintain catalytic competence of the enzyme. Supporting our observations, blocking of the PKC pathway was previously shown to decrease hyperglycaemia-caused apoptosis. Citrate is also a well-known Ca\(^{2+}\) chelator and could thus decrease PKC activation by blocking the Ca\(^{2+}\)-mediated translocation of PKC from the cytosol to the membrane. Several clinical studies on vascular function in diabetic patients have shown that inhibition of the PKC-β pathway has beneficial effects on vascular blood flow. However, the blocking of PKC-β did not affect the increased oxidative state in diabetic patients, suggesting that other isoforms of PKC, including alpha and delta, may participate in vascular dysfunction.

Hyperglycaemia-induced expression of adhesion molecules and the modulation of junctional permeability is one of the initial events of endothelial dysfunction and was recently shown to be mediated by the PKC pathways. In this study, both hyperglycaemia and 3,4-DGE were found to increase endothelial ICAM-1 expression, but the expression of VCAM-1 was not affected. Citrate treatment decreased both hyperglycaemia-induced ICAM-1 expression and hyperglycaemia-induced neutrophil diapedesis. However, citrate treatment did not decrease 3,4-DGE-induced ICAM-1 expression, although 3,4-DGE-induced neutrophil diapedesis was decreased by citrate treatment. This discrepancy between ICAM-1 expression and neutrophil diapedesis could indicate that citrate affects additional mechanisms involved in neutrophil diapedesis. On the other hand, the CAG combination exhibited a highly significant decrease of both hyperglycaemia- and 3,4-DGE-induced ICAM-1 expression. Furthermore, the combination significantly decreased both hyperglycaemia and 3,4-DGE-induced neutrophil diapedesis. These findings supports a previous report indicating that citrate improves the effect of other antioxidants.

A recent study in septic patients with hyperglycaemia showed increased neutrophil chemotaxis due to an increase of adhesion molecules. Furthermore, chemokine-driven leukocyte invasion of hyperglycaemic dysfunctional endothelium gives rise to inflammation and plaque formation. We observed only a minor increase of IL-6 and CXCL8 from hyperglycaemia- or 3,4-DGE-damaged cells in the infection model. Treatment with citrate significantly decreased IL-6 secretion from infected cells, but CXCL8 secretion was not significantly affected. However, the CAG combination decreased both cytokines, although the combination had the most impact on 3,4-DGE-induced CXCL8 secretion. Apart from the chelating capacities of citrates and gluconates, the positive effects of these compounds can originate from their quality as free radical scavengers, thereby blocking hyperglycaemia-induced ROS production. Additionally, citrate is known to maintain the glutathione (GSH)/oxidised glutathione (GSSG) ratio, the central component of the myocardial antioxidant system (reviewed by Mallet et al.).

To the best of our knowledge, this is the first study analysing the impact of citrate treatment on hyperglycaemia-damaged endothelial cells. Here we demonstrate that citrate treatment alone, or in combination with glucose, decreases PKC-β expression and mitigates both necrosis and apoptosis in hyperglycaemia- or 3,4-DGE-damaged cells. Citrate treatment was also shown to decrease endothelial inflammation by reducing ICAM-1 expression and cytokine production. Furthermore, the presence of citrate during hyperglycaemic conditions was shown to improve endothelial function by decreasing neutrophil diapedesis. Although very promising, these in vitro results should be correlated with in vivo studies using animal models. In summary, these results suggest that citrate alone or in combination with glucose can aid potential therapeutic approaches to endothelial dysfunction induced by hyperglycaemia.

**Funding**

This study was supported by a Research Scientist Grant from the Swedish Medical Research Council [grant no. 2008-5135].

**Conflict of interest**

None declared.

**References**

1. Shrishrimal K, Hart P and Michota F. Managing diabetes in hemodialysis patients: observations and recommendations. *Cleve Clin J Med* 2009; 76: 649–655.
2. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000; 321: 405–412.
3. Pearce LR, Komander D and Alessi DR. The nuts and bolts of AGC protein kinases. *Nat Rev Mol Cell Biol* 2010; 11: 9–22.
4. Idris I, Gray S and Donnelly R. Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. *Diabetologia* 2001; 44: 659–673.
5. Tomo T. Peritoneal dialysis solutions low in glucose degradation products – evidence for clinical benefits. *Perit Dial Int* 2008; 28(Suppl 3): S123–S127.
6. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? *Kidney Int* 2003; 63: 298–305.
7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature* 2001; 414: 813–820.
8. Bryland A, Broman M, Erixon M, Klarin B, Lindén T, Friberg H, et al. Infusion fluids contain harmful glucose degradation products. *Intensive Care Med* 2010; 36: 1213–1220.
9. Turina M, Fry DE and Polk HC, Jr. Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. *Crit Care Med* 2005; 33: 1624–1633.

10. Ata A, Lee J, Bestle SL, Desemone J and Stain SC. Postoperative hyperglycemia and surgical site infection in general surgery patients. *Arch Surg* 2010; 145: 858–864.

11. Erixon M, Wieslander A, Lindén T,Carlsson O, Jönsson JA, Simonsen O, et al. 3,4-DGE in peritoneal dialysis fluids cannot be found in plasma after infusion into the peritoneal cavity. *Perit Dial Int* 2008; 28: 277–282.

12. Kusunoki H, Miyata S, Ohara T, Liu BF, Uruihara A, Kojima H, et al. Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy. *Diabetes Care* 2003; 26: 1889–1894.

13. Erixon M, Wieslander A, Lindén T, Carlsson O, Forsbäck G, Svensson E, et al. Take care in how you store your PD fluids: actual temperature determines the balance between reactive and non-reactive GDPs. *Perit Dial Int* 2005; 25: 583–590.

14. Catalán, Santamaria B, Reyero A, Ortiz A, Egido J and Ortiz A. 3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis. *Kidney Int* 2005; 68: 1303–1311.

15. Tsuneki H, Sekizaki N, Suzuki T, Kobayashi S, Wada T, Okamoto T, et al. Coenzyme Q10 prevents high glucose-induced oxidative stress in human umbilical vein endothelial cells. *Eur J Pharmacol* 2007; 566: 1–10.

16. Rashid G, Benchetrit S, Fishman D and Bernheim J. Effect of advanced glycation end-products on gene expression and synthesis of TNF-alfa and endothelial nitric oxide synthase by endothelial cells. *Kidney Int* 2004; 66: 1099–1106.

17. Schuett H, Luchtefeld M, Grothuesen C, Grote K and Schieffer B. How much is too much? Interleukin-6 and its signalling in atherosclerosis. *Thromb Haemost* 2009; 102: 215–222.

18. Manduteau I, Voinea M, Serban G and Simionescu M. High glucose induces enhanced monocyte adhesion to valvular endothelial cells via a mechanism involving ICAM-1, VCAM-1 and CD18. *Endothelium* 1999; 6: 315–324.

19. Lawson C and Wolf S. ICAM-1 signaling in endothelial cells. *Pharmacol Rep* 2009; 61: 22–32.

20. Hamada Y, Nakashima E, Naruse K, Nakae M, Naika M, Fujisawa H, et al. A copper chelating agent suppresses carboxyl stress in diabetic rat lenses. *J Diabetes Complications* 2005; 19: 328–334.

21. Zheng Y, Li XY, Wang Y and Cai L. The role of zinc, copper and iron in the pathogenesis of diabetes and diabetic complications: therapeutic effects by chelators. *Hemoglobin* 2008; 32: 135–145.

22. Baynes JW and Murray DB. The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat. *Exp Diabetes Res* 2009; 2009: 696378.

23. Gabutti L, Ferrari L, Mombelli G, Keller F and Marone C. The favorable effect of regional citrate anticoagulation on interleukin-1beta release is dissociated from both coagulation and complement activation. *J Nephrol* 2004; 17: 819–825.

24. Bauer E, Derfler K, Joukhadar C and Drum W. Citrate kinetics in patients receiving long-term hemodialysis therapy. *Am J Kidney Dis* 2005; 46: 903–907.

25. Gabutti L, Lucchini B, Marone C, Alberio L and Burnier M. Citrate- vs. acetate-based dialysate in bicarbonate hemodialysis: consequences on haemodynamics, coagulation, acid-base status, and electrolytes. *BMC Nephrol* 2009; 10: 7.

26. Mak IT, Komarov AM, Kramer JH and Weglicki WB. Protective mechanisms of Mg-glucurate against oxidative endothelial cytotoxicity. *Cell Mol Biol (Noisy-le-grand)* 2000; 46: 1337–1344.

27. Repetto G, del Peso A and Zutri JL. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. *Nat Protoc* 2008; 3: 1125–1131.

28. Lindén T, Cohen A, Deppisch R, Kjellstrand P and Wieslander A. 3,4-Dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis. *Kidney Int* 2002; 62: 697–703.

29. Godaly G, Proudfoot AE, Offord RE, Svanborg C and Agace WW. Role of epithelial interleukin-8 (IL-8) and neutrophil IL-8 receptor A in *Escherichia coli*-induced transurethelial neutrophil migration. *Infect Immun* 1997; 65: 3451–3456.

30. Das Evcimen N and King GL. The role of protein kinase C activation and the vascular complications of diabetes. *Pharmacol Res* 2007; 55: 498–510.

31. Edwards AS, Faux MC, Scott JD and Newton AC. Carboxyterminal phosphorylation regulates the function and subcellular localization of protein kinase C betaII. *J Biol Chem* 1999; 274: 6461–6468.

32. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E and Cieriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P) H-oxidase activation. *Diabetes* 2003; 52: 2795–2804.

33. Casellini CM, Barlow PM, Rice AL, Casey M, Simmons K, Pittenger G, et al. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. *Diabetes Care* 2007; 30: 896–902.

34. Mehta NN, Sheetz M, Price K, Comisky L, Amrutia S, Iqbal N, et al. Selective PKC beta inhibition with ruboxistaurin decreases superoxide anion release in human umbilical vein endothelial cells. *J Diabetes Complications* 2010; 24: 135–145.

35. Venugopal SK, Devaraj S, Yang T and Jialal I. Alpha-tocopherol decreases superoxide anion release in human umbilical vein endothelial cells. *Diabetes* 2002; 51: 3049–3054.
on protein kinase C activation and independent of the Ca2+-
nitric oxide signalling pathway. Clin Exp Pharmacol Physiol
2005; 32: 771–776.
38. Mallet RT and Sun J. Antioxidant properties of myocardial
fuels. Mol Cell Biochem 2003; 253: 103–111.
39. Andreasen AS, Pedersen-Skovsgaard T, Berg RM, Svendsen
KD, Feldt-Rasmussen B, Pedersen BK, et al. Type 2 diabe-
tes mellitus is associated with impaired cytokine response
and adhesion molecule expression in human endotoxemia.
Intensive Care Med 2010; 36: 1548–1555.
40. Delamaire M, Maugendre D, Moreno M, Le Goff MC,
Allannic H and Genetet B. Impaired leucocyte functions in
diabetic patients. Diabet Med 1997; 14: 29–34.
41. Delvecchio C, Brizuela R, Khan S, Byer K, Li Z, Zhong P,
et al. Citrate and vitamin E blunt the shock wave-induced
free radical surge in an in vitro cell culture model. Urol Res
2005; 33: 448–452.
42. Bernstein EF, Brown DB, Schwartz MD, Kaidbey K and
Ksenzenko SM. The polyhydroxy acid gluconolactone pro-
tects against ultraviolet radiation in an in vitro model of
cutaneous photoaging. Dermatol Surg 2004; 30: 189–195;
discussion 196.
43. Murthi SB, Wise RM, Weglicki WB, Komarov AM and
Kramer JH. Mg-gluconate provides superior protection
against postischemic dysfunction and oxidative injury com-
pared to Mg-sulfate. Mol Cell Biochem 2003; 245: 141–148.